Pericyte coverage decreases invasion of tumour cells into blood vessels in prostate cancer xenografts

Prostate Cancer and Prostatic Diseases

Volumn 12, Issue 1, 2009, Pages 41-46

  Welen K ^a   Jennbacken, K ^a   Tesan T ^a   Damber, J E ^a  

^a SAHLGRENSKA ACADEMY AT UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; DENSITY; DISEASE COURSE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PERICYTE; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR CELL; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; ENDOTHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PERICYTES; PROSTATIC NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

EID: 60349112417     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2008.33     Document Type: Article

References (26)

1. Folkman J. Tumor angiogenesis: Therapeutic implications. New Engl J Med 1971; 285: 1182-1186.
2. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002; 160: 985-1000.
3. Papetti M, Herman IM. Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 2002; 282: C947-C970.
4. Bono AV, Celato N, Cova V, Salvadore M, Chinetti S, Novario R. Microvessel density in prostate carcinoma. Prostate Cancer Prostatic Dis 2002; 5: 123-127.
5. Khatami A, Pihl CG, Norrby K, Hugosson J, Damber JE. Is tumor vascularity in prostate core biopsies a predictor of PSA recurrence after radical prostatectomy? Acta Oncol 2005; 44: 362-368.
6. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143: 401-409.
7. Häggström S, Bergh A, Damber J-E. Vascular endothelial growth factor content in metastasizing and nonmetastasizing dunning prostatic adenocarcinoma. Prostate 2000; 45: 42-50.
8. Kosaka T, Miyajima A, Takayama E, Kikuchi E, Nakashima J, Ohigashi T et al. Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer. Prostate 2006; 67: 41-49.
9. Franck-Lissbrant I, Haggstrom S, Damber JE, Bergh A. Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinology 1998; 139: 451-456.
10. Häggström S, Lissbrant IF, Bergh A, Damber JE. Testosterone induces vascular endothelial growth factor synthesis in the ventral prostate in castrated rats. J Urol 1999; 161: 1620-1625.
11. Stewart RJ, Panigrahy D, Flynn E, Folkman J. Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: Evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol 2001; 165: 688-693.
12. Best CJ, Gillespie JW, Yi Y, Chandramouli GV, Perlmutter MA, Gathright Y et al. Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res 2005; 11: 6823-6834.
13. Gustavsson H, Welen K, Damber JE. Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis. Prostate 2005; 62: 364-373.
14. Gustavsson H, Jennbacken K, Welen K, Damber JE. Altered expression of genes regulating angiogenesis in experimental androgen-independent prostate cancer. Prostate 2008; 68: 161-170.
15. Jennbacken K, Gustavsson H, Welén K, Vallbo C, Damber J-E. Prostate cancer progression into androgen independency is associated with alterations in cell adhesion and invasivity. Prostate 2006; 66 1631-1640.
16. Tesan T, Jennbacken K, Welén K, Damber JE. Differential expression of angiopoietin-2 and vascular endothelial growth factor in androgen-independent prostate cancer models. BJU Int 2008; doi:10.1111/j.1464-410x.2008.07768.x.
17. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: Implications for antiangiogenic tumor therapies. Cancer Res 2000; 60: 1388-1393.
18. Xian X, Håkansson J, Ståhlberg A, Lindblom P, Betsholtz C, Gerhardt H et al. Pericytes limit tumor cell metastasis. J Clin Invest 2006; 116: 642-651.
19. Yonenaga Y, Mori A, Onodera H, Yasuda S, Oe H, Fujimoto A et al. Absence of smooth muscle actin-positive pericyte coverage of tumor vessels correlates with hematogenous metastasis and prognosis of colorectal cancer patients. Oncology 2005; 69: 159-166.
20. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: Significance of elevated interstitial pressure. Cancer Res 1988; 48: 7022-7032.
21. Netti PA, Roberge S, Boucher Y, Baxter LT, Jain RK. Effect of transvascular fluid exchange on pressure-flow relationship in tumors: A proposed mechanism for tumor blood flow heterogeneity. Microvasc Res 1996; 52: 27-46.
22. Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CY, Rajasekeran S et al Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007; 13: 3942-3950.
23. Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P et al Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004; 165: 35-52.
24. Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006; 116: 2610-2621.
25. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003; 111: 1287-1295.
26. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999; 103 159-165.